Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 26% ± 8% |
Insufficient scRNA-seq data for expression of FEM1A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 394.48 | 2639 / 2642 | 96% | 3.16 | 680 / 705 |
esophagus | 100% | 204.57 | 1442 / 1445 | 53% | 0.79 | 97 / 183 |
thymus | 100% | 194.12 | 650 / 653 | 30% | 0.48 | 179 / 605 |
kidney | 97% | 123.81 | 86 / 89 | 32% | 0.49 | 291 / 901 |
ovary | 98% | 186.83 | 177 / 180 | 26% | 0.37 | 113 / 430 |
adrenal gland | 84% | 79.43 | 216 / 258 | 39% | 0.72 | 89 / 230 |
bladder | 100% | 179.05 | 21 / 21 | 21% | 0.34 | 108 / 504 |
uterus | 100% | 248.34 | 170 / 170 | 21% | 0.35 | 98 / 459 |
intestine | 100% | 203.89 | 964 / 966 | 20% | 0.31 | 104 / 527 |
prostate | 100% | 243.05 | 245 / 245 | 13% | 0.18 | 67 / 502 |
stomach | 93% | 118.63 | 334 / 359 | 20% | 0.27 | 58 / 286 |
skin | 99% | 280.33 | 1793 / 1809 | 13% | 0.23 | 63 / 472 |
breast | 98% | 158.50 | 451 / 459 | 13% | 0.20 | 149 / 1118 |
lung | 96% | 158.17 | 553 / 578 | 14% | 0.18 | 156 / 1155 |
muscle | 100% | 3345.79 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 265.78 | 241 / 241 | 0% | 0 | 0 / 0 |
pancreas | 89% | 90.42 | 292 / 328 | 11% | 0.28 | 19 / 178 |
heart | 99% | 340.66 | 854 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 97% | 133.86 | 1297 / 1335 | 0% | 0 | 0 / 0 |
adipose | 96% | 128.78 | 1160 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 90% | 111.22 | 833 / 929 | 0% | 0 | 0 / 0 |
liver | 46% | 37.42 | 103 / 226 | 2% | 0.03 | 9 / 406 |
lymph node | 0% | 0 | 0 / 0 | 31% | 0.46 | 9 / 29 |
tonsil | 0% | 0 | 0 / 0 | 24% | 0.44 | 11 / 45 |
eye | 0% | 0 | 0 / 0 | 4% | 0.04 | 3 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0051438 | Biological process | regulation of ubiquitin-protein transferase activity |
GO_0140627 | Biological process | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0005739 | Cellular component | mitochondrion |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0031867 | Molecular function | EP4 subtype prostaglandin E2 receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FEM1A |
Protein name | Protein fem-1 homolog A (FEM1a) (FEM1-alpha) (Prostaglandin E receptor 4-associated protein) |
Synonyms | EPRAP |
Description | FUNCTION: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation . The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms . The CRL2(FEM1A) complex specifically recognizes proteins with an arginine at the C-terminus: recognizes and binds proteins ending with -Lys/Arg-Xaa-Arg and -Lys/Arg-Xaa-Xaa-Arg C-degrons, such as SIL1 or OR51B2, leading to their ubiquitination and degradation . Promotes ubiquitination and degradation of SLBP . Involved in PGE2-EP4-mediated inhibition of inflammation of macrophages via interaction with NFKB1 and PTGER4 (By similarity). Promotes inflammation in brain microglia through MAP2K4/MKK4-mediated signaling (By similarity). . |
Accessions | Q9BSK4 ENST00000269856.5 |